Wilate FDA Approval History
FDA Approved: Yes (First approved December 4, 2009)
Brand name: Wilate
Generic name: von Willebrand Factor/Coagulation Factor VIII Complex (Human)
Dosage form: Injection
Company: Octapharma USA
Treatment for: von Willebrand Disease, Hemophilia A
Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human)) is used in the management of von Willebrand disease and hemophilia A.
- Wilate is indicated in children and adults with von Willebrand disease for:
- on-demand treatment and control of bleeding episodes
- perioperative management of bleeding
- routine prophylaxis to reduce the frequency of bleeding episodes. Wilate is indicated for routine prophylaxis in children 6 years of age and older and adults with von Willebrand disease. - Wilate is indicated in adolescents and adults with hemophilia A for:
- routine prophylaxis to reduce the frequency of bleeding episodes
- on-demand treatment and control of bleeding episodes.
Development timeline for Wilate
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
